1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Leveraging New Approach Methodologies and Non-Animal Technologies to Accelerate Osteoarthritis Research is sponsored by National Institutes of Health (NIH). Invites research grant applications that utilize New Approach Methodologies (NAMs) and Non-Animal Technologies (NATs)—such as non-invasive imaging techniques—to investigate the biological mechanisms driving the initiation and progression of osteoarthritis (OA).
This could encompass advanced ultrasound imaging of the knee.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Leveraging New Approach Methodologies and Non-Animal Technologies to Accelerate Osteoarthritis Research | Grants & Funding U.S. Department of Health and Human Services National Institutes of Health Leveraging New Approach Methodologies and Non-Animal Technologies to Accelerate Osteoarthritis Research When beginning your next investigator-initiated application, consider the following NIH highlighted topic.
The area of science described below is of interest to the listed NIH Institutes, Centers, and Offices (ICOs). This is not a notice of funding opportunity (NOFO). Apply through an appropriate NIH Parent Funding Announcement or another broad NIH opportunity available on Grants.
gov . Learn how to interpret and use Highlighted Topics . Post Date: August 29, 2025 Expiration Date: August 29, 2027 We invite research grant applications that utilize New Approach Methodologies (NAMs) and Non-Animal Technologies (NATs)—such as archived human joint tissues, organoids, tissue chips, advanced in vitro systems, computational and mathematical models, and non-invasive imaging techniques.
When appropriately justified, applications may also incorporate combinations of these approaches with animal models, including genetically modified mouse models and underutilized large animal models, to investigate the biological mechanisms driving the initiation and progression of osteoarthritis (OA).
While aging and obesity are important risk factors for OA, research efforts in the past have focused primarily on the more advanced stages of OA. Relatively little is understood about the initial changes triggering disease etiology and early progression.
While traditional animal models remain essential for scientific discovery, emerging technologies present unique advantages that—when applied effectively or in combination—can significantly broaden the research toolkit, enabling scientists to tackle biomedical questions that were previously impossible to address.
The National Institutes of Health (NIH) is launching the NAM/NAT initiative to prioritize innovative, human-relevant science while promoting a reduction in animal use. This effort aligns with the U.S. Food and Drug Administration’s (FDA) recent commitment to minimizing reliance on animal testing for drug development. Examples of possible topics include, but are not limited to: Molecular characterization of joint degeneration phenotypes.
Age-related changes in chondrogenic stem cells and their role in OA onset. Age-related metabolic changes contributing to OA development. Influence of the aging immune system on OA initiation.
Early alterations at the chondro-osseous junction. Interactions between inflammatory signals and joint, bone, and synovial responses. Role of pro-inflammatory molecules in cartilage degradation Signaling pathways mediating inflammation-driven joint degeneration.
Mechanotransduction pathways linking physical loading to gene expression in joints. Contributions of non-cartilaginous joint tissues (nerves, synovium, muscle, fat, tendon) to OA pathology. Mapping genetic loci and downstream effectors involved in joint degeneration.
Roles of cellular senescence and aging-associated epigenetic changes. Gene-gene and gene-environment interactions influencing OA susceptibility. Mechanisms by which physical activity may alleviate OA symptoms.
Integration of regenerative medicine and rehabilitation strategies. Development of regenerative rehabilitation approaches to enhance tissue repair and functional recovery in patients with knee OA.
Central Scientific Contact: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) In addition to the topics listed above, NIAMS area of interest includes investigations of the biological mechanisms driving the initiation and progression of osteoarthritis (OA). IC may give special consideration to support meritorious applications in this topic area.
National Institute on Aging (NIA) For technical issues E-mail OER Webmaster
According to the current listing, eligibility includes: Research grant applications from eligible institutions, including universities. Confirm the full requirements in the official notice before applying.
Applications for Leveraging New Approach Methodologies and Non-Animal Technologies to Accelerate Osteoarthritis Research are due August 29, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Leveraging New Approach Methodologies and Non-Animal Technologies to Accelerate Osteoarthritis Research is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The Health and Extreme Weather highlighted topic went live September 1, 2026 with eleven awarding institutes and expires May 1, 2028. There is no set-aside, no separate deadline, and no review criteria — which makes the institute-by-institute language the only real signal, and it is not uniform.
Read articleThe NOURISH Autoimmunity Digital Health Challenge runs three phases to August 2028: 10 winners at $20,000, then 5 at $30,000, then 3 at $100,000. It is a prize competition, not a grant — no indirect costs, no cost reimbursement, and a rule that quietly disqualifies the obvious applicant.
Read articlePAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read article